← Back to Search

Anti-bacterial agent

Doxycycline 100 mg for Heart Failure (DOXY-HF Trial)

Phase 2
Waitlist Available
Led By Antonio Abbate, M.D.
Research Sponsored by Virginia Commonwealth University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 14 days
Awards & highlights
All Individual Drugs Already Approved
Approved for 60 Other Conditions

Summary

Non-ischemic cardiomyopathy and heart failure are highly influenced by the presence of systemic inflammation. Doxycycline is a FDA-approved drug to treat bacterial infections which also shows powerful anti-inflammatory effects. In this study we plan to determine the effects of Doxycycline in patients with stable heart failure and non-ischemic cardiomyopathy on peak of aerobic exercise capacity (peak V02) and ventilator efficiency measured with a cardiopulmonary test.

Eligible Conditions
  • Heart Failure
  • Non Ischemic Cardiomyopathy

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~14 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 14 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Peak Aerobic Exercise Capacity

Side effects data

From 2022 Phase 4 trial • 449 Patients • NCT04050540
3%
Malaria
100%
80%
60%
40%
20%
0%
Study treatment Arm
Standard of Care Arm
dPEP Intervention Arm

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 60 Other Conditions
This treatment demonstrated efficacy for 60 other conditions.

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: Doxycycline 20 mgExperimental Treatment1 Intervention
Doxycycline 20 mg twice daily for 14 days
Group II: Doxycycline 100 mgExperimental Treatment1 Intervention
Doxycycline 100 mg twice daily for 14 days
Group III: PlaceboPlacebo Group1 Intervention
Placebo
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Doxycycline
FDA approved

Find a Location

Who is running the clinical trial?

Virginia Commonwealth UniversityLead Sponsor
714 Previous Clinical Trials
22,888,385 Total Patients Enrolled
25 Trials studying Heart Failure
4,792 Patients Enrolled for Heart Failure
Antonio Abbate, M.D.Principal InvestigatorVirginia Commonwealth University
~1 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top